Company intelligence / Profile preview

SynAgile

Wilson, Wyoming, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Phase 2

Overview

SynAgile has reported positive top-line results from a Phase 2 clinical trial for its DopaFuse® Levodopa-Carbidopa Delivery System in patients with Parkinson's disease. The system enables continuous oral drug delivery and aims to improve symptom management in these patients.

Therapeutic areas: Neurology
Modalities: Drug delivery systems (notably non-invasive continuous oral drug delivery)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

levodopa + carbidopa

Phase 2

Indications: Parkinson's disease

Beyond the preview

Go deeper on SynAgile.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SynAgile.

Explore the full profile